Last updated on July 2019

GB001 in Adult Subjects With Chronic Rhinosinusitis

Brief description of study

A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GB001 compared with placebo over 16 weeks of treatment in patients with chronic rhinosinusitis with or without nasal polyposis (NP).

Clinical Study Identifier: NCT03956862

Find a site near you

Start Over

Kentuckiana Ear, Nose, and Throat

Louisville, KY United States
  Connect »

Advanced ENT and Allergy

Louisville, KY United States
  Connect »